title: Gene therapy progress and prospects: reprograming gene expression by trans-splicing.
abstract: The term 'trans-splicing' encompasses several platform technologies that combine two RNA or protein molecules to generate a new, chimeric product. RNA trans-splicing reprograms the sequences of endogenous messenger mRNA or pre-mRNA, converting them to a new, desired gene product. Trans-splicing has broad applications, depending on the nature of the sequences that are inserted or trans-spliced to the defined target. Trans-splicing RNA therapy offers significant advantages over conventional gene therapy: expression of the trans-spliced sequence is controlled by the endogenous regulation of the target pre-mRNA; reduction or elimination of undesirable ectopic expression; the ability to use smaller constructs that trans-splice only a portion of the gene to be replaced; and the conversion of dominant-negative mutations to wild-type gene products.
authors.affiliation: Intronn Inc., Gaithersburg, MD 20878, USA.
authors.forename: L G
authors.initials: LG
authors.lastname: Mitchell
authors.forename: G J
authors.initials: GJ
authors.lastname: McGarrity
mesh_terms: D000818:Animals; D005786:Gene Expression Regulation; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D009154:Mutation; D012326:RNA Splicing; D012333:RNA, Messenger / Q000008:administration & dosage / Q000235:genetics; D017381:Spliceosomes; D020040:Trans-Splicing; D014162:Transfection
chemical_list: D012333:RNA, Messenger